# OrsoBio

> OrsoBio is a privately held, clinical-stage biopharmaceutical company founded in 2021 and
> headquartered in Palo Alto, California. It develops first-in-class oral therapies that restore
> energy homeostasis in patients living with severe metabolic disorders — obesity, type 2 diabetes,
> severe dyslipidemias, lipodystrophies and MASH. OrsoBio does not run a developer program and
> publishes no API.

<!--
generated: 2026-08-04
method: generated
source: apis.yml + live probes of orsobio.com on 2026-08-04
note: Generated by the API Evangelist enrichment pipeline. OrsoBio does not publish an llms.txt of
      its own — https://orsobio.com/llms.txt returns the site's 404 page.
-->

## About

OrsoBio takes its name from the metabolic adaptability of bears ("orso" in Italian), which avoid
serious metabolic consequences through hibernation. The company's therapies target fundamental
pathways of energy metabolism. It closed an oversubscribed $67 million Series B in September 2024,
co-led by Ascenta Capital and Woodline Partners, with Samsara BioCapital, Enavate Sciences and
Longitude Capital participating.

## Pipeline

- Mitochondrial protonophores TLC-6740, TLC-1180, TLC-1235 — increase energy expenditure to improve
  metabolic and cardiovascular health in obesity and associated metabolic conditions, and in
  lipodystrophies.
- LXR inverse agonist TLC-2716 — improve plasma triglycerides, cholesterol and hepatic steatosis in
  severe hypertriglyceridemia and MASH.
- ACC2 inhibitor TLC-3595 — improve insulin sensitivity in type 2 diabetes.
- ACMSD inhibitor — augment NAD+ biosynthesis and improve mitochondrial function in metabolic and
  inflammatory liver and/or kidney disorders.

## Site

- [Home](https://orsobio.com/)
- [About](https://orsobio.com/about/)
- [Science](https://orsobio.com/science/)
- [Pipeline](https://orsobio.com/our-pipeline/)
- [Team](https://orsobio.com/team/)
- [News](https://orsobio.com/news/): press releases, in-the-news coverage and events
- [News feed (RSS)](https://orsobio.com/feed/)
- [Privacy Policy](https://orsobio.com/privacy-policy/)
- [LinkedIn](https://www.linkedin.com/company/orsobio/)

## APIs

OrsoBio publishes no API. As of 2026-08-04 there is no developer portal, no API documentation, no
SDK, no OpenAPI/AsyncAPI/GraphQL contract, no MCP server and no A2A agent card. No `api.`,
`developer.`, `docs.`, `portal.` or `status.` host resolves for orsobio.com, and no `orsobio` GitHub
organisation exists. The site's own WordPress content-management routes under `/wp-json/` are
disallowed by https://orsobio.com/robots.txt and are not a developer offering; agents should not
treat them as an API.

Automated requests to orsobio.com are answered by a SiteGround CAPTCHA interstitial (HTTP 202,
`sg-captcha: challenge`, `x-robots-tag: noindex`), so the site is effectively closed to unattended
agents.

## API Evangelist profile

- [apis.yml](https://raw.githubusercontent.com/api-evangelist/orsobio/refs/heads/main/apis.yml)
- [Well-known / discovery probe results](https://raw.githubusercontent.com/api-evangelist/orsobio/refs/heads/main/well-known/orsobio-well-known.yml)
- [Domain security probe](https://raw.githubusercontent.com/api-evangelist/orsobio/refs/heads/main/security/orsobio-domain-security.yml)